Treatment of Nodular Syphilis

Introduction to Nodular Syphilis Treatment

The Centers for Disease Control and Prevention recommends benzathine penicillin G 2.4 million units intramuscularly weekly for 3 consecutive weeks (total 7.2 million units) for the treatment of nodular syphilis, a manifestation of late/tertiary syphilis 1, 2

The Centers for Disease Control and Prevention recommends benzathine penicillin G 2.4 million units intramuscularly once weekly for 3 consecutive weeks as the first-line treatment for tertiary syphilis, including nodular manifestations, with a total dose of 7.2 million units 3, 4, 5, 6, 1, 2
This extended regimen is necessary because nodular syphilis represents late-stage disease requiring more prolonged treponemacidal levels than the single-dose regimen used for early syphilis 2

The Centers for Disease Control and Prevention recommends that all patients with nodular/tertiary syphilis must undergo CSF examination to exclude neurosyphilis before initiating the standard tertiary syphilis regimen 5, 1, 2
HIV testing is mandatory for all patients with syphilis, as HIV co-infection may affect treatment response and requires more frequent monitoring 3, 4, 5, 1

For non-pregnant penicillin-allergic patients, the Centers for Disease Control and Prevention recommends doxycycline 100 mg orally twice daily for 28 days as the preferred alternative for late syphilis 2
Tetracycline 500 mg orally four times daily for 28 days is another option, though compliance is typically better with doxycycline due to less frequent dosing and fewer gastrointestinal side effects 3, 4, 6
Pregnant patients with penicillin allergy must undergo desensitization followed by penicillin treatment, as no alternative antibiotics are proven effective for preventing fetal complications 4, 5, 1, 2

Clinical and serologic evaluation (quantitative nontreponemal tests like RPR or VDRL) should be performed at 6, 12, and 24 months after treatment, with a fourfold decline in nontreponemal test titers expected within 12-24 months for late syphilis 4, 6, 1, 2
HIV-infected patients require more frequent monitoring at 3-month intervals due to higher risk of treatment failure 4, 6, 1

Treatment failure is defined as persistent or recurring clinical signs/symptoms, or a sustained fourfold increase in nontreponemal test titers, and patients with suspected treatment failure should be re-evaluated for HIV infection and undergo CSF examination to exclude neurosyphilis 4, 6, 1, 2
Re-treatment typically consists of benzathine penicillin G 2.4 million units intramuscularly weekly for 3 weeks, unless CSF examination indicates neurosyphilis requiring IV penicillin therapy 3, 4, 5, 1

Jarisch-Herxheimer reaction (acute fever, headache, myalgia occurring within 24 hours of treatment) may occur, particularly in patients with active lesions, and patients should be counseled about this expected reaction 1, 2
If a weekly dose is missed during the 3-week regimen, an interval of 10-14 days between doses is acceptable before needing to restart the entire sequence 2
Serologic tests may remain positive indefinitely in patients with prior syphilis infections (serofast state), and treponemal tests (FTA-ABS, TP-PA) remain positive for life and should not be used to monitor treatment response 1, 2